The DAC Inhibitor, LBH589, Is Highly Effective in Both Rituximab-Sensitive and Rituximab-Resistant Lymphomas and Enhances the Anti-Tumor Activity of Bortezomib, Other Chemotherapy Agents, and Anti-CD20 Monoclonal Antibodies.
Hernandez-Ilizaliturri F, Marvis C, Maraj I, Chisti M, Gibbs J, Czuczman M. The DAC Inhibitor, LBH589, Is Highly Effective in Both Rituximab-Sensitive and Rituximab-Resistant Lymphomas and Enhances the Anti-Tumor Activity of Bortezomib, Other Chemotherapy Agents, and Anti-CD20 Monoclonal Antibodies. Blood 2009, 114: 2715. DOI: 10.1182/blood.v114.22.2715.2715.Peer-Reviewed Original ResearchPatient-derived primary tumor cellsB-cell lymphomaPrimary tumor cellsChemotherapy agentsAnti-tumor activityMonoclonal antibodiesTumor cellsPolymerase chain reactionLymphoma cell linesCell linesAnti-CD20 Monoclonal AntibodyRoswell Park Cancer InstituteLarge B-cell lymphomaState Cancer CenterCD20 monoclonal antibodySignificant anti-tumor activitySequence of administrationQualitative polymerase chain reactionAnti-tumor effectsPotent treatment strategyNHL cell linesCombination of LBH589Primary lymphoma cellsResistant cell linesSensitive cell linesEfficacy of the DAC inhibitor LBH589 in both rituximab-sensitive and rituximab-resistant lymphomas and effect on the antitumor activity of chemotherapy agents, monoclonal antibodies, and bortezomib
Maraj I, Hernandez-Ilizaliturri F, Chisti M, Czuczman M. Efficacy of the DAC inhibitor LBH589 in both rituximab-sensitive and rituximab-resistant lymphomas and effect on the antitumor activity of chemotherapy agents, monoclonal antibodies, and bortezomib. Journal Of Clinical Oncology 2009, 27: 8576-8576. DOI: 10.1200/jco.2009.27.15_suppl.8576.Peer-Reviewed Original ResearchRituximab-sensitive cell linesRituximab-resistant cell linesCell linesB-cell lymphomaBcl-2 family membersPatient-derived tumor cellsChemotherapy agentsNHL cell linesMonoclonal antibodiesPatient-derived tumour cellsBcl-xL geneCellular processesTumor cellsEffects of LBH589Polymerase chain reactionGene transcriptionGene expressionTarget proteinsAlamar Blue reductionMitochondrial potentialAntitumor activityNegative selectionSequence of administrationQualitative polymerase chain reactionCell titer